Vitamin E δ-
tocotrienol has been shown to have antitumor activity, but the precise molecular mechanism by which it inhibits the proliferation of
cancer cells remains unclear. Here, we demonstrated that δ-
tocotrienol exerted significant cell growth inhibition pancreatic ductal
cancer (PDCA) cells without affecting normal human pancreatic ductal epithelial cell growth. We also showed that δ-
tocotrienol-induced growth inhibition occurred concomitantly with G(1) cell-cycle arrest and increased p27(Kip1) nuclear accumulation. This finding is significant considering that loss of nuclear p27(Kip1) expression is a well-established adverse prognostic factor in PDCA. Furthermore, δ-
tocotrienol inactivated RAF-
MEK-ERK signaling, a pathway known to suppress p27(Kip1) expression. To determine whether p27(Kip1) induction is required for δ-
tocotrienol inhibition of PDCA cell proliferation, we stably silenced the CDKN1B gene, encoding p27(Kip1), in MIAPaCa-2 PDCA cells and demonstrated that p27(Kip1) silencing suppressed cell-cycle arrest induced by δ-
tocotrienol. Furthermore, δ-
tocotrienol induced p27(Kip1)
mRNA expression but not its protein degradation. p27(Kip1) gene promoter activity was induced by δ-
tocotrienol through the promoter's E2F-1 binding site, and this activity was attenuated by E2F-1 depletion using E2F-1
small interfering RNA. Finally, decreased proliferation, mediated by Ki67 and p27(Kip1) expression by δ-
tocotrienol, was confirmed in vivo in a nude mouse xenograft
pancreatic cancer model. Our findings reveal a new mechanism, dependent on p27(Kip1) induction, by which δ-
tocotrienol can inhibit proliferation in PDCA cells, providing a new rationale for p27(Kip1) as a
biomarker for δ-
tocotrienol efficacy in
pancreatic cancer prevention and
therapy.